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Plasma cholesteryl ester transfer protein (CETP) med-
iates CE and triacylglycerol (TG) transfer or exchange
among lipoproteins and is a major regulator of high
density lipoprotein (HDL) cholesterol levels as well as
non-HDL cholesterol in humans. By inhibiting CETP,
diet-induced atherosclerosis was attenuated in choles-
terol-fed rabbits, suggesting a novel therapeutic approach
toward coronary artery disease with low HDL levels in
humans [1–3]. However, there are considerable concerns
regarding the efficacy of chemical CETP inhibitor in
humans, as suggested in recent genetic population
studies.
Extensive genotyping has been performed in the CETP
gene, revealing its complex role in atherogenicity [4].
Several nonsynonymous coding polymorphisms, such as
D442G and I405V, were reported to have direct or
indirect effects on CETP and HDL levels. Population
studies suggested that the genotypes associated with lower
CETP levels are pro-atherogenic in men and women [5,6].
However, promoter variation or its linked polymorph-
ism may have different consequences. TaqIB polymorph-
ism, first analysed a decade ago, provides a mystery to be
solved. This site is located at the 1 277 nucleotide of
intron 1. Despite no apparent functional sequence in the
TaqIB site, the TaqIB2 allele (no restriction sequence) was
associated with lower CETP and/or higher HDL. This
TaqIB2 genotype has been consistently anti-atherogenic in
several different population studies [7–9]. Population
admixture is unlikely to explain this association. Thus,
the controversial association among low CETP, high HDL
and antiatherogenicity of TaqIB2 is opposite to the results
in I405V and D442G studies. Functionally, the TaqIB2
genotype may play an anti-atherogenic role in humans,
probably mediated by a modified very low density
lipoprotein (VLDL) secretion rate, increased low density
lipoprotein (LDL) size [9], and direct effects of higher
HDL and lower LDL. Another explanation would be
linkage disequilibrium between undefined causative pro-
moter variation and TaqIB.
Indirect effects via linkage disequilibrium with near
regulatory nucleotide variations or those in a nearby gene
may exist with the TaqIB2 allele. Such examples,
2 629C/A and [gaaa] repeat, were disclosed recently
[10,11]. This promoter variation of the 2629A allele,
located at the Sp1/Sp3 recognition site, had 25%
decreased promoter activity, 23% lower CETP, and
12% higher HDL levels [10]. In this issue of the
European Journal of Clinical Investigation, Kakko et al.
examined the association between 2629C/A and several
polymorphisms in the CETP gene [12]. They found that
the 2629 A/A genotype increased HDL levels by 16%
only in women, independent of plasma CETP activity.
The 2629A-TaqIB2 allele is strongly linked with 373 A
in exon12, and 451R in exon15. Also, they suggested
three category groups of –629C/A-TaqIB, A373P-R451Q
and I405V as independent and interactive variables of
CETP, HDL, and carotid atherosclerosis. Interestingly,
7–10% of the variation in carotid atherosclerosis could be
explained by CETP gene polymorphisms. Similarly,
Corbex et al. [13] examined CETP gene polymorphisms
extensively, and showed associations of 373A with high
HDL, and 451R with low HDL, revealed by four stratified
genotypes of 373 and 451, although such an effect was not
detected by analysis of each single genotyping. By studying
two common polymorphisms of A373P and R451Q,
Agerholm-Larsen et al. [14] demonstrated that the 373P-
451Q allele is associated with lower HDL levels, but
paradoxically, is also associated with lower coronary risk in
women not receiving hormone replacement therapy.
However, an opposite trend was found in men and
women administered with hormone replacement therapy.
Interestingly, the 373P-451Q allele is completely linked
with 2629C-TaqIB1 (known as pro-atherogenic in pre-
vious studies), in the study by Kakko et al. [12]. In
addition, the association with carotid atherosclerosis in
373P was opposite between the sexes: pro-atherogenic in
women, but antiatherogenic in men [12].
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Thus, results analysed by single polymorphism geno-
typing may be confounded by other polymorphism(s) in
linkage disequilibrium. It is likely that marginal effects on
phenotype could not be detected by univariate analysis of
each of two sites because of linkage disequilibrium between
them, when they have opposite effects on phenotype.
Similarly, phenotypic effect would be exaggerated by the
analysis of single polymorphism genotyping when another
polymorphism in linkage disequilibrium has a similar effect.
In future, we should learn more regarding the promoter
variation of CETP gene in longer lengths. Some population
studies have shown that TaqIB2 and 2629A alleles are
associated with increased HDL levels, independent of
plasma CETP activity [4,7,12], although the underlying
mechanism has not been clarified. This phenomenon could
be explained by environmental effects such as alcohol
intake, or confounding effects by linkage disequilibrium
between one polymorphism with low CETP and another
with high CETP. Thus, whether nucleotide variation(s) of
CETP promoter or its linked polymorphism(s) associated
with lower CETP levels is really antiatherogenic or an
incidental finding should be investigated.
This complexity noted in CETP gene association
studies suggests that haplotyping or analysis of selected
polymorphisms evaluated by linkage disequilibrium para-
meter is needed for genotype–phenotype association
before mass screening. Also, careful interpretation is
required in genetic epidemiological surveys when deter-
mining any disease associations.
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